Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trialYung‐Jue Bang, Yoon‐Koo Kang, Eric Van Cutsem et al.|The Lancet|2010Cited by 7.3k
Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody CetuximabKimio Yonesaka, Pasi A. Jänne, Kreshnik Zejnullahu et al.|Science Translational Medicine|2011Cited by 670
Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 studyArvind Dasari, Cathy Eng, Pilar García‐Alfonso et al.|The Lancet|2023Cited by 319
Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III StudyLin Shen, Ken Kato, Sung‐Bae Kim et al.|Journal of Clinical Oncology|2022Cited by 306